

Combined pharmacological and physical interventions following neurological injury


T. George Hornby, PT, PhD

Associate Professor, Department of Physical Therapy and
Kinesiology and Nutrition, University of Illinois at Chicago

Director, Locomotor Recovery Laboratory,
Research Scientist, Sensory Motor Performance Program,
Rehabilitation Institute of Chicago


Outline

- Single dose agents do not significantly/substantially effect function
 - Divergent effects on volitional and reflex motor behaviors
 - No effect of functional task performance
- Effects of combined pharmacological and physical interventions



Influences of descending monoaminergic agents


- Bulbospinal pathways provide modulatory (5HT/NE) inputs to spinal circuits
 - Inhibit afferent/pain input (5HT₁, NE α 2)
 - Activate central circuits (5HT₇, NE α 2)
 - Modulate motoneurons (NE α 1, 5HT₂)
- Partially restore 5HT influences with broad-spectrum 5HT facilitators (SSRIs)
- Problem? Super-sensitivity, constitutively active 5HT receptors – recovery of volitional strength and reflex activity




Escitalopram influences volitional and reflex excitability

- SSRIs generate moderate increases in maximal volitional contractions in lower extremities (Gourab et al 2015; c.f., however F. Chollet)

A: peak torques





B: MG EMG activity





Escitalopram influences volitional and reflex excitability

- SSRIs generate moderate increases in maximal volitional contractions in lower extremities (Gourab et al 2015; c.f., however F. Chollet)
- SSRIs also increases reflex excitability during passive stretch



Escitalopram influences volitional and reflex excitability

- SSRIs generate moderate increases in maximal volitional contractions in lower extremities (Gourab et al 2015; c.f., however F. Chollet)
- SSRIs also increases reflex excitability during passive stretch (stroke and SCI)




Escitalopram influences volitional and reflex excitability

- SSRIs generate moderate increases in maximal volitional contractions in lower extremities (Gourab et al 2015; c.f., however F. Chollet)
- SSRIs also increases reflex excitability during passive stretch (stroke and SCI)
- Somewhat consistent with previous effects in upper extremity, although limited previous mention of increased abnormal responses (Stolp-Smith and Wainberg 1999)
 - Mono- to di-synaptic pathways
 - None to few intermediary interneurons



Cyproheptadine vs escitalopram

- Divergent responses of 5HT agents on volitional and reflex excitability (Thompson et al 2013 – incomplete SCI)




Cyproheptadine vs escitalopram

- Divergent responses of 5HT agents on volitional and reflex excitability (Thompson et al 2013 – incomplete SCI)





Cyproheptadine vs escitalopram

- Effects on locomotor performance
 - Stroke: Gourab et al 2015




Cyproheptadine vs escitalopram

- Effects on locomotor performance
 - Stroke: Gourab et al 2015
 - SCI: Leech et al 2014




Cyproheptadine vs escitalopram

- Effects on locomotor performance
 - Stroke: Gourab et al 2015
 - SCI: Leech et al 2014
- Exaggerated effects with superimposed volitional activity (dorsiflexion MVCs with plantarflexor stretch)



Outline

- Single dose agents do not significantly/substantially effect function
 - Divergent effects on volitional and reflex motor behaviors
 - No effect of functional task performance
- **Effects of combined pharmacological and physical interventions**




Chronic doses with training

- Randomized, blinded clinical trial

- 8 weeks treadmill training with and without SSRI administration
- SSRIs/placebo only on days of training
- 34 ambulatory subjects > T10 incomplete SCI

- Results

- Significant difference in changes in peak treadmill speeds
- Significant difference in modified Ashworth scores favoring control group
- Spasticity may not matter



Current/future directions- single/chronic doses in subacute SCI

- Single dose responses – prior to following acute SSRI administration


Pre to Post-SSRI administration



Pre-testing stepping attempts



Post-SSRI stepping attempts



↑
Step #1

↑
Step #2


↑
Step #3

Acknowledgements

- University of Illinois at Chicago
- Northwestern University
 - Kristan Leech, PT, DPT
 - CJ Heckman, PhD
 - W. Zev Rymer, MD, PhD
 - Chris Thompson, PT, PhD
- Rehabilitation Institute of Chicago
 - Catherine Kinnaird, MS
 - Jennifer Moore, PT, DHS, NCS
 - Jennifer Kahn, PT, NCS
 - Carey Holleran, PT, DHS, NCS
- Marquette University
 - Brian Schmit, PhD
 - Krishnaj Gourab, MD

Results – Single dose study: muscle activity patterns

- Significantly worse MG timing (SLDI) with SSRI vs placebo (drug * test interaction)
- No other differences noted – trend towards worsening with SSRIs




Results – Repeated doses-LT study: spatiotemporal parameters


- *Significant* improves favoring SSRI vs placebo on treadmill only:

- **D Peak speed**
(0.17 ± 0.17 vs 0.05 ± 0.15 m/s $p < 0.001$)

A. Fastest Treadmill Speed




B. Cadence




- **D paretic step length**
(0.09 ± 0.08 vs 0.03 ± 0.07 m, $p < 0.01$)

C. Step Length - Paretic Side (fastest speed)



D. Step Length - nonParetic Side (fastest speed)



- **D non-paretic step length** (0.10 ± 0.10 vs 0.01 ± 0.08 m; $p = 0.02$)

- No difference in cadence ($p = 0.25$)